TY - JOUR
T1 - Biomarkers in inflammatory bowel disease
T2 - Current practices and recent advances
AU - Iskandar, Heba N.
AU - Ciorba, Matthew A.
N1 - Funding Information:
This work was supported in part by the National Institutes of Health Grants DK089016 and L30 RR030244 (M.A.C.) as well as the Division of Gastroenterology’s 5T32DK007130-38 (H.N.I.).
PY - 2012/4
Y1 - 2012/4
N2 - Crohn's disease and ulcerative colitis represent the two main forms of the idiopathic chronic inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers provide reproducible, quantitative tools that can complement clinical assessment to aid clinicians in IBD diagnosis and management. C-reactive protein and fecal based leukocyte markers can help the clinician distinguish IBD from noninflammatory diarrhea and assess disease activity. The ability to differentiate between forms of IBD and predict risk for disease complications is specific to serologic tests including antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins. Advances in genomic, proteomic, and metabolomic array based technologies are facilitating the development of new biomarkers for IBD. The discovery of novel biomarkers, which can correlate with mucosal healing or predict long-term disease course has the potential to significantly improve patient care. This article reviews the uses and limitations of currently available biomarkers and highlights recent advances in IBD biomarker discovery.
AB - Crohn's disease and ulcerative colitis represent the two main forms of the idiopathic chronic inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers provide reproducible, quantitative tools that can complement clinical assessment to aid clinicians in IBD diagnosis and management. C-reactive protein and fecal based leukocyte markers can help the clinician distinguish IBD from noninflammatory diarrhea and assess disease activity. The ability to differentiate between forms of IBD and predict risk for disease complications is specific to serologic tests including antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins. Advances in genomic, proteomic, and metabolomic array based technologies are facilitating the development of new biomarkers for IBD. The discovery of novel biomarkers, which can correlate with mucosal healing or predict long-term disease course has the potential to significantly improve patient care. This article reviews the uses and limitations of currently available biomarkers and highlights recent advances in IBD biomarker discovery.
UR - http://www.scopus.com/inward/record.url?scp=84858386087&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2012.01.001
DO - 10.1016/j.trsl.2012.01.001
M3 - Review article
C2 - 22424434
AN - SCOPUS:84858386087
SN - 1931-5244
VL - 159
SP - 313
EP - 325
JO - Translational Research
JF - Translational Research
IS - 4
ER -